

# Heterogeneity of PET/CT imaging phenotype prognostic in mCRPC

November 16 2017

---



(HealthDay)—Metastatic castration-resistant prostate cancer (mCRPC)

has heterogeneity in positron emission tomography (PET)/computed tomography (CT) imaging phenotype, which has clinical relevance, according to a study published online Nov. 9 in *JAMA Oncology*.

Josef J. Fox, M.D., from Memorial Sloan Kettering Cancer Center in New York City, and colleagues performed PET/CT imaging with fluoro-2-D-deoxyglucose F 18 for glycolysis (Glyc) and fluorodihydrotestosterone F 18 for [androgen receptor](#) (AR) expression to determine heterogeneity of imaging phenotypes. A total of 133 patients with mCRPC underwent imaging.

The researchers found that each phenotype had an independent negative impact on survival in multivariate analysis, which was most pronounced for AR<sub>0</sub>Glyc<sub>1</sub> [lesions](#), followed by AR<sub>1</sub>Glyc<sub>1</sub> lesions and AR<sub>1</sub>Glyc<sub>0</sub> lesions (hazard ratios, 1.11, 1.05, and 1.03, respectively). Four patient-specific groups emerged when sorted by lesion type: concordant, with all AR<sub>1</sub>Glyc<sub>1</sub>; AR predominant, with AR<sub>1</sub>Glyc<sub>1</sub> and varying numbers of AR<sub>1</sub>Glyc<sub>0</sub>; Glyc predominant, with AR<sub>1</sub>Glyc<sub>1</sub> and varying numbers of AR<sub>0</sub>Glyc<sub>1</sub>; and mixed, with AR<sub>1</sub>Glyc<sub>1</sub> plus AR<sub>1</sub>Glyc<sub>0</sub> and AR<sub>0</sub>Glyc<sub>1</sub>.

"With regard to mCRPC lesions, most express ARs, consistent with initial benefit of ARSi [androgen receptor-signaling inhibitor] drugs," the authors write. "On a patient basis, 49 percent (groups 3 and 4) had at least one AR<sub>0</sub>Glyc<sub>1</sub> lesion—the imaging phenotype with the most negative effect on survival, possibly due to ARSi resistance."

Several authors disclosed financial ties to the pharmaceutical industry.

**More information:** [Abstract/Full Text \(subscription or payment may be required\)](#)

Copyright © 2017 [HealthDay](#). All rights reserved.

Citation: Heterogeneity of PET/CT imaging phenotype prognostic in mCRPC (2017, November 16) retrieved 2 May 2024 from <https://medicalxpress.com/news/2017-11-heterogeneity-petct-imaging-phenotype-prognostic.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.